Anti-drawback medical valve

Information

  • Patent Grant
  • 7753892
  • Patent Number
    7,753,892
  • Date Filed
    Tuesday, February 15, 2005
    19 years ago
  • Date Issued
    Tuesday, July 13, 2010
    13 years ago
Abstract
A medical valve has an interior flow path having a volume that is substantially the same when in either the closed mode (when the valve is closed) or the open mode (when the valve is open). To those ends, the medical valve has a housing forming an interior, and a valve mechanism (within the interior) having a substantially rigid translating member with a bore. The interior of the housing has a flow path that includes at least a portion of the bore of the translating member. As noted above, the open mode volume is substantially equal to the closed mode volume.
Description
FIELD OF THE INVENTION

The invention generally relates to medical valves and, more particularly, the invention relates to medical valves that substantially eliminate fluid drawback.


BACKGROUND OF THE INVENTION

In general terms, medical valving devices often act as a sealed port that may be repeatedly accessed to non-invasively inject fluid into (or withdraw fluid from) a patient's vasculature. Consequently, a medical valve permits the patient's vasculature to be freely accessed without requiring such patient's skin be repeatedly pierced by a needle.


Medical personnel insert a syringe into the proximal port of a properly secured medical valve to inject fluid into (or withdraw fluid from) a patient. Once inserted, the syringe may freely inject or withdraw fluid to and from the patient. Problems arise, however, when the syringe is withdrawn from many different types of prior art valves. Specifically, a back pressure (i.e., a proximally directed pressure) produced by the withdrawing syringe undesirably can cause blood to be drawn proximally into a catheter attached to the valve, or into the valve itself. In addition to coagulating and impeding the mechanical operation of the valve, blood in the catheter or valve also compromises sterility.


SUMMARY OF THE INVENTION

In accordance with one aspect of the invention, a medical valve has an interior flow path having a volume that is substantially the same when in either the closed mode (when the valve is closed) or the open mode (when the valve is open). To those ends, the medical valve has a housing forming an interior, and a valve mechanism (within the interior) having a substantially rigid translating member with a bore. The interior of the housing has a flow path that includes at least a portion of the bore of the translating member. As noted above, the open mode volume is substantially equal to the closed mode volume.


In some embodiments, the flow path has a volume that remains substantially constant as the valve transitions between the open mode and the closed mode. Moreover, the flow path may have at least a portion of the bore and a second portion. In that and other cases, the translating member may extend through the second portion of the flow path. The second portion also may have a substantially constant volume as the valve transitions between modes.


The interior also may include a receiving chamber that is outside of the flow path. The translating member illustratively extends into the receiving chamber when the valve is in the closed mode. In addition, the translating member may have a substantially static shape as the valve transitions between the open mode and the closed mode.


In illustrative embodiments, the valve substantially has neither a positive push nor a drawback when the valve transitions from the open mode to the closed mode. In a similar manner, the valve may substantially have neither a positive push bolus nor a drawback bolus when the valve transitions from the closed mode to the open mode. Moreover, movement of the translating member may cause substantially no volumetric change within any part of the flow path when the valve transitions between the open and closed modes.


Among other things, the translating member includes a cannula or a tube. In yet other embodiments, the valve mechanism has a proximal section and the housing also has a distal port. In that and other cases, the flow path may extend from the proximal section of the valve mechanism to the distal port.


In accordance with another aspect of the invention, a medical valve has a housing forming an interior having a proximal port and a distal port, and the interior forms a flow path between the proximal port and the distal port. The valve also has a translating member (having a bore) that is longitudinally movable within the interior. The flow path includes the bore and a second portion that is bounded by the translating member. The flow path maintains a substantially constant volume when the valve transitions between the open mode and the closed mode.


The second portion preferably remains substantially stationary within the interior when the valve transitions between the open and closed modes. In addition, the bore may maintain a substantially constant volume between the open and closed modes. The valve also may have an elastomeric member (within the interior) that prevents fluid flow through the bore when the valve is in the closed mode. In this and other cases, the bore may have at least two longitudinally spaced openings normally occluded by the elastomeric member when the valve is in the closed mode.


In some embodiments, the valve also has a valve mechanism that includes the translating member and the elastomeric member. The valve mechanism may be substantially flush with or extends proximally from the proximal port when the valve is in the closed mode. Other embodiments configure the second portion of the flow path to have a part with a first boundary and a second boundary. In that and other cases, the translating member may extend at least from the first boundary to the second boundary. Moreover, the translating member may bound the second portion of the flow path in both the closed mode and in the open mode.


In accordance with another aspect of the invention, a medical valve has a housing having a distal port and an interior, and a valve mechanism within the interior. The valve mechanism has a sealing member, while the interior has components forming a flow path extending from the sealing member and terminating at the distal port. The sealing member cooperates with at least one of the components to selectively open and close the valve. The components each maintain substantially constant shapes as the valve transitions between the open mode and the closed mode. The distal port substantially has neither a positive push nor a drawback when the valve transitions from the open mode to the closed mode.


In accordance with another aspect of the invention, a method of controlling fluid flow through a valve forms a flow path within the valve interior. The formed flow path has a first portion and a second portion. The method longitudinally moves the first portion relative to the second portion to change the mode of the valve. Each of the first portion and the second portion has a substantially static shape when the valve transitions between the open mode and the closed mode.





BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and advantages of the invention will be appreciated more fully from the following further description thereof with reference to the accompanying drawings wherein:



FIG. 1 schematically shows a medical valve that may be configured in accordance with illustrative embodiments of the invention.



FIG. 2 schematically shows a cross-sectional view of the medical valve shown in FIG. 1 configured in accordance with one embodiment of the invention.



FIGS. 3A and 3B schematically show cross-sectional view of the valve shown in FIG. 1 in a closed mode and configured in accordance with a second embodiment of the invention.



FIGS. 4A and 4B schematically show cross-sectional view of the valve embodiment shown in FIGS. 3A and 3B in an open mode.



FIG. 5 schematically shows an alternative embodiment of the proximal end of the valve shown in FIG. 1.



FIG. 6 schematically shows a cross-sectional view of the medical valve shown in FIG. 1 configured in accordance with a third embodiment of the invention.





DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

In illustrative embodiments, a medical valve substantially has neither a positive push nor a drawback at any point in its opening or closing stroke. To those ends, such a valve illustratively has a flow path that maintains a substantially static shape and thus, a substantially constant volume, throughout the opening or closing stroke. Details of illustrative embodiments are discussed below.



FIG. 1 schematically shows a medical valve 10 that may be configured to substantially eliminate fluid drawback (a/k/a “back-flow”) while a syringe or other type of nozzle is connecting to or withdrawing from it. The valve 10 has a valve housing 12 forming an interior 13 having proximal and distal ports 14 and 16 (also respectively referred to herein as “inlet 14” and “outlet 16”). The interior 13 contains a valve mechanism (various embodiments of the valve mechanism are shown in the subsequent figures) that controls fluid flow through the valve 10. The fluid preferably is in liquid form, such as saline or a liquid medication, to pass through a fluid path that extends between the inlet 14 and the outlet 16. Although much of the discussion herein refers to the proximal port 14 as a fluid inlet, and the distal port 16 as a fluid outlet, the proximal and distal ports 14 and 16 also may be respectively used as outlet and inlet ports.


As discussed below, the valve 10 has components that are similar to the luer-activated swab valve disclosed in U.S. Pat. No. 6,039,302 entitled, “SWABBABLE LUER-ACTIVATED VALVE,” the disclosure of which is incorporated herein, in its entirety, by reference. Of course, various embodiments may relate to other types of valves and thus, such embodiments are not limited to swab valves and/or luer-activated valves. Other embodiments are related to valves shown in the pending U.S. patent application Ser. Nos. 09/479,327 and 09/812,237, the disclosures of which are incorporated herein, in their entireties, by reference.



FIG. 2 schematically shows a cross-sectional view along line X-X of one embodiment of the valve 10 shown in FIG. 1. The housing 12 includes inlet and outlet housing portions 18 and 20, which illustratively are formed from a hard plastic material (e.g., polycarbonate, polypropylene, or polyethylene) that are snap-fit together. For example, the housing portions 18 and 20 may be configured to snap fit together in accordance with the teachings of co-pending, commonly owned U.S. patent application Ser. No. 10/265,292, filed Oct. 4, 2002, the disclosure of which is incorporated herein, in its entirety, by reference. It should be noted that although some embodiments are discussed as being snap-fit components, various embodiments of the invention may be coupled by either snap-fit or other means, such as by ultrasonic welding. Accordingly, such embodiments are not intended to be limited to snap-fit components.


When coupled, the housing portions 18 and 20 form the interior 13, which is shaped to comply with the operation of its internal valve element (discussed below) that selectively permits fluid flow. The proximal port 14, which is part of the interior 13, illustratively is contoured to accept various types of nozzles, such as those complying with ANSI/ISO standards (e.g., luers complying with ANSI and/or ISO standards).


The valve mechanism includes a stretchable and compressible gland 22A secured between the inlet housing portion 18 and outlet housing portion 20, a rigid and longitudinally movable cannula 24A secured within the valve 10 by the gland 22A, and a membrane 26 to partially occlude fluid flow from the cannula 24A.


The cannula 24A includes a proximal section that is coupled with a distally located thin section. In illustrative embodiments, the thin section is a hollow needle (identified by reference number “28”) that, together with the proximal section, forms a flow path (referred to below as a “bore” and identified by reference number 36). The needle 28 is open at its proximal end, closed at its distal end, and has a hole 30 in its side just proximal to its distal end. When in the closed position (i.e., the “closed mode,” which prevents fluid flow through the valve 10), the hole 30 is occluded by the membrane 26, which is held fixed between outlet housing portion 20 and the gland 22A.


The outlet housing portion 20 forms a chamber 32 (within the housing interior 13) having a volume that, in some embodiments, changes slightly as the needle 28 is urged proximally and distally by a nozzle. In one embodiment, the volume of the chamber 32 is slightly greater when in the closed mode than when in the open mode. This slight difference in volume is due to the volume of the needle 28 extending into the chamber 32.


Insertion of a nozzle against a slit 34 at the proximal end of the gland causes the cannula 24A to move distally, thereby moving the hole 30 from its occluding contact with the membrane 26. Liquid consequently may be directed first through the cannula flow path and hole 30, then through the chamber 32, and out of the valve 10 through the distal port 16.


In an illustrative embodiment of the invention, the needle 28 is sized to be very thin. The amount of fluid drawn back into the chamber 32 as the nozzle is withdrawn corresponds to the volume of the needle 28 required to expose the hole 30 to the chamber 32. Consequently, as suggested above, this volume is controlled by the needle diameter and the placement of the hole 30. By making the diameter of the needle 28 small and the hole 30 very close to the distal end of the needle 28, the volume of fluid drawn back into the chamber 32 is reduced and the subsequent risk from contamination to the valve 10 minimized. In certain embodiments, the volume of fluid drawn back upon withdrawal of the nozzle is on the order of between about one and several microliters. In some embodiments, the total volume of fluid drawn back is on the order of about 0.5 microliters.


In some embodiments, a bump or other type of protrusion can be included on the needle 28 to pull (i.e., stretch) the membrane 26 back beyond its normally neutral position. In so doing, the membrane 26 is pulled to a point at which the membrane 26 will be released from the bump on the needle 28. As the membrane 26 returns to its neutral position, it pushes fluid forward through the outlet (referred to herein as “positive push”). In still other embodiments, the bump may be a part of the membrane 26.


It is contemplated that the amount of fluid pushed forward/distally by this bump can be controlled to cancel out with the amount of drawback caused by the needle 28 returning into the membrane 26. In other words, the volume of the internal chamber 32 remains substantially constant as the valve 10 transitions between the open and closed modes. When this occurs, a meniscus at the distal port 16 (when the distal port 16, or end of a catheter to which it is attached, is facing upwardly) will be substantially unchanged as the nozzle is withdrawn from the valve 10.


Accordingly, in this case, the valve 10 has neither a positive push nor a drawback when the it transitions from the open mode to the closed mode. In practice, this embodiment can have negligible amounts in either direction (e.g., less then one microliter). This design, which has insubstantial/negligible drawback and/or positive push, thus may be considered to have a “neutral” drawback.


In illustrative embodiments, the distal end of the needle 28 is bulbous to facilitate its movement through the membrane 26. In such embodiment, the hole 30 is located immediately above the bulbous distal end. In other embodiments, the membrane 26 and gland 22A are a single unitary molded part.



FIGS. 3A and 3B schematically show cross-sectional views of the valve 10 configured in accordance with a second embodiment of the invention. Specifically, in this and related embodiments, the valve 10 is configured to have a neutral drawback. Ideally, a neutral drawback has 0.0 microliters of positive or negative drawback. As suggested above, however, in practice, a neutral drawback actually can have a very slight positive or negative drawback (i.e., a manufacturing tolerance), such as a drawback on the order of positive or negative one microliter, or less. For anticipated applications, any such drawback is considered to be negligible.


In a manner similar to other embodiments, the valve 10 in this embodiment has a housing 12 with inlet and outlet housing portions 18 and 20 forming an interior 13, and a plurality of components forming a valve mechanism within the interior 13. The components forming the valve mechanism include a substantially rigid and longitudinally movable cannula 24B having an internal bore 36 making up a part of the internal valve flow path, and a stretchable and compressible gland 22B secured between the inlet and outlet housing portions 18 and 20 for both biasing and sealing the cannula 24B.


In illustrative embodiments, the gland 22B is formed from an elastomeric material, such as silicone or rubber. Other materials having similar properties may be used, however, so long as they can perform the functions discussed herein. The gland 22B has several cooperating sections for controlling fluid flow through the valve 10 while substantially eliminating fluid drawback. Namely, the gland 22B has a proximal section 38 having a slit 34, a central section 40 tightly circumscribing the cannula 24B and having optional vents 78, and an attachment section 42 for securing the gland 22B within the valve 10.


The cannula 24B may be any tube or other substantially rigid apparatus, such as a hollow needle, that may be configured to perform the discussed functions. As discussed below, the cannula 24B can be formed from a sufficiently rigid material that substantially prevents its body from bending during use. For example, among other things, the cannula 24B may be formed from a liquid crystal polymer, an elastomer, polycarbonate, polyethylene or polypropylene.


In the embodiment shown in FIGS. 3A and 3B, the bore 36 extends from the proximal section 38 of the gland 22B to a longitudinally extending solid cannula portion 44. Specifically, the bore 36 extends from an opening 46 at its proximal end, to holes 30 in its side. The solid cannula portion 44 is distal of the holes 30. When in the closed mode, the gland 22B normally occludes the holes 30 by means of an interference fit (e.g., on the order of 5-10 thousands of an inch). In addition, the proximal section 38 of the gland 22B normally occludes the opening 46 at the proximal end of the cannula 24B when in the closed mode. Accordingly, the valve 10 is considered to have a proximal seal formed by the slit proximal section 38 of the gland 22B, and an interior seal formed by the interference fit of the gland 22B about the portion of the cannula 24B having the holes 30.


When the valve 10 is in the closed mode/position, the proximal section 38 of the gland 22B is flush with, or extends slightly above, the exterior inlet face of the housing 12 (see, for example, FIGS. 3A and 3B). The proximal section 38 and the exterior inlet face thus present a swabbable surface. In other words, the proximal section 38 and the exterior inlet face may be easily wiped clean by any conventional means, such as with an alcohol swab. Valves having swabbable surfaces are known in the art as “swabbable valves.” In other embodiments, however, the valve 10 is not a swabbable valve.


In accordance with illustrative embodiments of the invention, the flow path is configured to have a neutral drawback. To that end, the flow path is considered to have a movable first portion (i.e., a “dynamic portion 50,” which in this embodiment comprises the bore 36), and a static second portion (a “static portion 52”) that cooperates with the dynamic portion 50 to provide the neutral drawback. Longitudinal movement of the cannula 24B relative to the static portion 52 controls the mode of the valve 10.


One or more components cooperate to form the static portion 52 of the flow path. Among other things, those components may be integrated into the housing 12 (e.g., by conventional injection molding processes), or be separate parts inserted into the housing interior 13. For example, when separate parts, the components may include a basket 54 containing an insert 56, and a spacer 58 for forming at least one wall of the static portion 52 of the flow path. The basket 54, insert 56, and spacer 58 illustratively are formed from the same material as the housing 12 (e.g., a hard plastic). Discussion of such components, however, is exemplary and not intended to limit the scope of various embodiments.


In either case, the static portion 52 of the flow path includes a radially extending portion (formed by radially extending walls and referred to as the “first radial path 60”) that terminates at a tapered wall. The tapered wall may form a substantially longitudinally directed flow path 62 that terminates in a more distally located radially extending flow path portion (“second radial path 64”). The flow path continues to a longitudinally directed distal flow path 66 that terminates at the distal port 16 of the valve 10. During and between both modes of use, the cannula 24B is considered to meet at/form a substantially consistently sized boundary with at least part of the static portion 52 of the flow path.


To facilitate cannula movement, the interior 13 of the valve 10 forms a vented receiving chamber 68 for receiving the distal end of the cannula 24B during and between all modes of use of the valve 10. The receiving chamber 68, however, is outside of the flow path and thus, has a substantially nonmovable ring seal 70 that separates its interior from the flow path. In illustrative embodiments, the ring seal 70 is upwardly tapered and formed from a material having some pliability, and yet does not move a sufficient amount to displace a non-negligible fluid volume. For example, the ring seal 70 may be formed from an elastomeric or semi-rigid material (e.g., polyethylene or polypropylene), which may be applied in a two-shot molding process. In alternative embodiments, the ring seal 70 may be formed from the same material as that used to form the housing 12. Accordingly, the ring seal 70 seals against the movable cannula 24B to isolate the receiving chamber 68 from the flow path. The ring seal 70 therefore also may be considered to form a boundary with the static portion 52 of the flow path.


In illustrative embodiments, the interior 13 of the housing 12 contains a plurality of additional flow paths that are configured to be substantially identical to that discussed above with regard to the static portion 52 of the flow path. For example, FIGS. 3A and 3B show at least two flow paths that each are configured as discussed above and together form the static portion 52 of the flow path. In fact, the respective first radially extending paths of both paths of the embodiment shown in FIGS. 3A and 3B may be considered to form a single first radially extending path through which the cannula 24B extends. Specifically, the cannula 24B extends from a proximally located boundary 72 (of the single radially extending flow path) to a distally located boundary 74 during and between both modes of use of the valve 10.


In addition to not moving relative to the housing 12, the static portion 52 of the flow path also maintains a substantially static shape during and between all modes of use. In other words, the shape of the static portion 52 does not change during and between all modes of use. The walls also neither expand nor contract. Movement of the cannula 24B should not be considered to affect the shape of the static portion 52.


As shown in FIGS. 4A and 4B, insertion of a nozzle (e.g., an ANSI/ISO standard luer) into the proximal port 14 forces the gland 22B and cannula 24B to move distally to an open position. As shown, this causes the cannula holes 30 to move longitudinally away from occluding contact with the gland 22B at about the same time. In addition, a combination of forces cooperate to open the slit 34. Among those forces is the response of the gland 22B to the longitudinal force of the nozzle. In addition, the inner diameter of the housing 12 is smaller near the proximal port 14. After tapering for a relatively short distance, however, the inner diameter of the housing 12 expands significantly, thus permitting the proximal section 38 of the gland 22B to more freely open the slit 34.



FIG. 5 schematically shows an alternative embodiment of the proximal end of the valve 10, in which the proximal section 38 of the gland 22B extends radially outwardly and about the outer surface of the proximal port 14. In essence, such a gland 22B forms a type of “trampoline” about the proximal port 14. Such an embodiment effectively forms a proximal spring that provides an additional radially directed opening force for the slit 34. In addition, the spring also acts as a diaphragm for preventing inadvertent leakage of fluid from the nozzle in the space between the gland 22B and the housing 12 (i.e., the interstitial space). This seal is not necessary to keep such fluid from the flow path, however, because the attachment section 38 of the gland 22B acts as a fluid barrier.


When in the open position, the formerly non-contiguous flow path becomes contiguous between the open proximal end 46 of the cannula 24B and the distal port 16 of the valve 10. More specifically, the flow path within the interior 13 of the housing 12 is considered to be formed through the following sequential portions:

    • The proximal opening 46 of the cannula 24B,
    • The bore 36 in the cannula 24B,
    • Through the cannula holes 30,
    • The first radial path 60 of the static portion 52,
    • The longitudinally directed flow path 62,
    • The second radial path 64 of the static portion 52,
    • The distal flow path 66, and
    • Through the distal port 16.


More specifically, to open the valve, the nozzle applies a distally directed force directly against the top of the proximal section 38 of the gland 22B. When the distally directed force exceeds the proximally directed biasing force of the gland 22B, the cannula 24B and gland 22B begin translating distally. Consequently, the central section 40 of the gland 22B begins to deform, such as in the convoluted manner shown in FIG. 4A. It is anticipated, however, that the gland 22B may deform in some other way, such as by bulging radially or compressing without bulging or convoluting, while maintaining contact against the cannula wall. It should be noted that the cannula holes 30 should remain occluded until they extend distally of the gland 22B.


Distal movement of the cannula 24B also forces air from the receiving chamber 68 through a chamber vent 76. Accordingly, air in the receiving chamber 68 should not present an additional impedance for opening the valve. Moreover, gland vents 78 prevent the gland 22B from forming a vacuum that could potentially draw fluid from a fluid path through the cannula holes 30. Of course, the gland vents 78 are positioned so that they do not interfere with the role of the central section 40 of the gland 22B in occluding the cannula holes 30. In alternative embodiments, other means may be used to ensure that fluid does not escape from the flow path and into the space between the gland 22B and the cannula 24B. For example, an o-ring may be secured about the gland 22B to fill the space between the gland 22B and inner wall of the housing 12. Such means should further ensure the interference fit of the gland 22B. As a second example, the valve also may have additional material at the distal end of the gland 22B to provide additional sealing functionality.


As it translates distally, the cannula 24B does not displace any additional volume in the flow path. In particular, as the cannula 24B translates along the boundary of the first radial path 60 (of the static portion 52 of the flow path), it does not positively or negatively displace fluid within the priming volume of the static portion 52. Instead, it displaces a constant amount of the interior of the static portion 52 of the flow path; namely, the volume in FIGS. 3A, 3B, 4A, and 4B between the two first radial flow paths 60. Accordingly, although the cannula 24B translates into this area, an equal amount of the cannula 24B translates from this area and into the receiving chamber 68. The internal volume of the static portion 52 therefore remains static, thus not inducing a positive or negative vacuum at the distal port 16.


At some point during the opening stroke of the valve, the cannula holes 30 break through their occluding contact with the gland 22B and contact the second portion of the flow path (i.e., at the first radial portion). Those skilled in the art should understand that this movement should have no more than a negligible impact on the volume of the flow path because it simply joins two constant volume paths (i.e., the dynamic and static portions 50 and 52 of the flow path). In particular, during and between all modes of use, the bore 36 has a constant bore volume, while the static portion 52 also has a constant second volume. Distal movement of the bore 36 simply directly fluidly connects these two volumes. Accordingly, when in the open mode, the cannula holes 30 essentially are positioned along/form the boundary of the static portion 52 of the flow path. The cannula holes 30 thus also may be considered to “bound” the second portion of the flow path.


Removal of the nozzle similarly enables the restoring force of the gland 22B to force the cannula 24B proximally. Because the internal volumes and/or shape of the flow path remain substantially static, there should be no positive or negative pressure formed at the distal port 16 (despite its relative movement). In particular, the total volume of the flow path is substantially the same in both the open mode and closed mode. In fact, in illustrative embodiments, the total volume of the flow path remains substantially constant during and between both modes. As noted above, this result is due largely to the shifting, substantially constant volumes and static shapes/walls of the two portions of the flow path. Accordingly, the distal port 16 should have a neutral drawback both when inserting a nozzle into, and removing a nozzle from, the proximal port 14.


Although not necessary, a line leading to the valve also can be clamped while a nozzle is connected or withdrawn from the valve 10. Unlike various prior art valves, however, the valve 10 still should return to its closed, swabbable position because, among other reasons, it produces neither a negative nor positive vacuum at the distal port 16. Of course, clamping the line should be unnecessary when using the valve 10.



FIG. 6 schematically shows another embodiment of the invention, in which the bore 36 extends substantially along the entire length of the cannula 24C. In addition, the flow path of this embodiment also has a small portion with deformable (i.e., non-static) walls formed by the gland 22C. Moreover, the ring seal 70 of this embodiment is not tapered proximally. In this embodiment, however, the ring seal 70 may be flexible enough to compensate for volume changes in other portions of the flow path, if any such portions exist. Those skilled in the art can selectively combine these and features of other embodiments to form a valve having the desired functionality.


Although the above discussion discloses various exemplary embodiments of the invention, it should be apparent that those skilled in the art can make various modifications that will achieve some of the advantages of the invention without departing from the true scope of the invention.

Claims
  • 1. A medical valve having an open mode that permits fluid flow, and a closed mode that prevents fluid flow, the medical valve comprising: a housing forming an interior;a valve mechanism within the interior, the valve mechanism having a substantially rigid translating member with a bore and an elastomeric member sealing the bore in the closed mode,the interior of the housing having a flow path that includes at least a portion of the bore of the translating member,the flow path having an open mode volume when the valve is in the open mode, the fluid path also having a closed mode volume when the valve is in the closed mode, the open mode volume being substantially equal to the closed mode volume, and movement of the translating member causing substantially no volumetric change within any part of the flow path when the valve transitions between the open and closed modes.
  • 2. The medical valve as defined by claim 1 wherein the flow path has a volume that remains substantially constant as the valve transitions between the open mode and the closed mode.
  • 3. The medical valve as defined by claim 1 wherein the flow path comprises the at least a portion of the bore and a second portion, the translating member extending through the second portion of the flow path.
  • 4. The medical valve as defined by claim 1 wherein the interior also includes a receiving chamber that is outside of the flow path, the translating member extending into the receiving chamber when the valve is in the closed mode.
  • 5. The medical valve as defined by claim 1 wherein the flow path comprises the at least a portion of the bore and a second portion, the second portion having a substantially constant volume as the valve transitions between modes.
  • 6. The medical valve as defined by claim 1 wherein the translating member has a substantially static shape as the valve transitions between the open mode and the closed mode.
  • 7. The medical valve as defined by claim 1 wherein the valve substantially has neither a positive push nor a drawback when the valve transitions from the open mode to the closed mode.
  • 8. The medical valve as defined by claim 1 wherein the valve substantially has neither a positive push nor a drawback when the valve transitions from the closed mode to the open mode.
  • 9. The medical valve as defined by claim 1 wherein the translating member includes a cannula.
  • 10. The medical valve as defined by claim 1 wherein the valve mechanism has a proximal section, the housing also having a distal port, the flow path extending from the proximal section of the valve mechanism to the distal port.
  • 11. A medical valve having an open mode that permits fluid flow, and a closed mode that prevents fluid flow, the medical valve comprising: a housing forming an interior having a proximal port and a distal port, the interior forming a flow path between the proximal port and the distal port,a translating member having a bore, the translating member being longitudinally movable within the interior, the flow path comprising the bore and a second portion,the translating member bounding the second portion of the flow path, the flow path maintaining a substantially constant volume when the valve transitions between the open mode and the closed mode; andan elastomeric member normally biasing the translating member to close the valve, the elastomeric member sealing the bore when in the closed mode.
  • 12. The medical valve as defined by claim 11 wherein the second portion remains substantially stationary within the interior when the valve transitions between the open and closed modes.
  • 13. The medical valve as defined by claim 11 wherein the bore maintains a substantially constant volume between the open and closed modes.
  • 14. The medical valve as defined by claim 11 wherein movement of the translating member causes substantially no volumetric change within any part of the flow path when the valve transitions between the open and closed modes.
  • 15. The medical valve as defined by claim 11 wherein the elastomeric member is within the interior, the elastomeric member preventing fluid flow through the bore when the valve is in the closed mode.
  • 16. The medical valve as defined by claim 15 wherein the bore has at least two longitudinally spaced openings, the elastomeric member occluding the at least two longitudinally spaced openings when the valve is in the closed mode.
  • 17. The medical valve as defined by claim 11 further comprising a valve mechanism, the valve mechanism including the translating member and the elastomeric member, the valve mechanism being substantially flush with or extending proximally from the proximal port when the valve is in the closed mode.
  • 18. The medical valve as defined by claim 11 wherein the translating member includes a tube.
  • 19. The medical valve as defined by claim 18 wherein the tube has a side wall forming an opening, the side wall terminating at a closed distal end, the opening being occluded when the valve is in the closed mode.
  • 20. The medical valve as defined by claim 11 wherein the interior has a receiving chamber outside the flow path, the translating member being at least partly within the receiving chamber when the valve is in the closed mode.
  • 21. The medical valve as defined by claim 11 wherein the second portion of the flow path has a part with a first boundary and a second boundary, the translating member extending at least from the first boundary to the second boundary.
  • 22. The medical valve as defined by claim 11 wherein the second portion of the flow path has at least one radially extending wall.
  • 23. The medical valve as defined by claim 11 wherein the distal port substantially has neither a positive push nor a drawback when the valve transitions from the open mode to the closed mode.
  • 24. The medical valve as defined by claim 11 wherein the translating member bounds the second portion of the flow path in both the closed mode and in the open mode.
  • 25. The medical valve as defined by claim 11 wherein the second portion of the flow path remains substantially static as the valve transitions between the open mode and the closed mode.
  • 26. A method of controlling fluid flow through a valve having an interior, the valve having an open mode that permits fluid flow, and a closed mode that prevents fluid flow, the method comprising: forming a flow path within the interior, the flow path comprising a first portion and a second portion;inserting a nozzle into the valve; andlongitudinally moving the first portion relative to the second portion to change the mode of the valve, each of the first portion and the second portion having a substantially static shape when the valve transitions between the open mode and the closed mode, the nozzle longitudinally moving the first portion relative to the second portion as the nozzle is inserted into the valve, the valve having an elastomeric member that seals the first portion of the flow path when in the closed mode.
  • 27. The method as defined by claim 26 wherein the first portion has a substantially constant volume when the valve transitions between the open mode and the closed mode, the second portion having a substantially constant volume when the valve transitions between the open mode in the closed mode.
  • 28. The method as defined by claim 26 wherein the valve has a distal port substantially having neither a positive push nor a drawback when the first portion longitudinally moves relative to second portion.
  • 29. The method as defined by claim 26 wherein the flow path has a substantially constant volume when the first portion longitudinally moves relative the second portion.
  • 30. The method as defined by claim 26 wherein a first component forms the first portion, the first component displacing a displacement volume within the second portion, the displacement volume remaining substantially constant as the valve transitions between the open mode and the closed mode.
  • 31. The method as defined by claim 26 wherein the first portion bounds the second portion in both the open mode and the closed mode.
  • 32. The method as defined by claim 26 wherein a line is connected to the valve, the first portion of the flow path being in a closed position when in the closed mode, the method further comprising: clamping the line when in the open mode, the first portion of the flow path returning to the closed position when the line is clamped.
  • 33. A medical valve having an open mode that permits fluid flow, and a closed mode that prevents fluid flow, the medical valve comprising: a housing having a distal port and an interior,a valve mechanism within the interior, the valve mechanism having an elastomeric sealing member,the interior having components forming a flow path extending from the elastomeric sealing member and terminating at the distal port, the elastomeric sealing member cooperating with at least one of the components to selectively open and close the valve, the elastomeric sealing member normally biasing at least one of the components to close the valve, andthe components each maintaining substantially constant shapes as the valve transitions between the open mode and the closed mode,the distal port substantially having neither a positive push nor a drawback when the valve transitions from the open mode to the closed mode.
  • 34. The medical valve as defined by claim 33 wherein the distal port substantially has neither a positive push nor a drawback when the valve transitions from the closed mode to the open mode.
  • 35. The medical valve as defined by claim 33 wherein the components include: a first component forming a first portion of the flow path; anda second component forming a second portion of the flow path,the first component moving relative to the second component as the valve transitions from the open mode to the closed mode.
  • 36. The medical valve as defined by claim 35 wherein the first portion and second portion of the flow path are not in fluid communication during the closed mode.
  • 37. The medical valve as defined by claim 33 wherein the components comprise a translating member having a bore, the flow path comprising the bore and a second portion, the translating member bounding the second portion of the flow path during both the open mode and closed mode.
  • 38. The medical valve as defined by claim 33 wherein the entire flow path maintains a substantially constant volume as the valve transitions from the open mode to the closed mode.
  • 39. The medical valve as defined by claim 33 wherein the components define the entire flow path through the valve.
  • 40. The medical valve as defined by claim 33 wherein the components comprise at least one of a translating member and an interior contour of the housing.
  • 41. A medical valve having an open mode that permits fluid flow, and a closed mode that prevents fluid flow, the medical valve comprising: a housing forming an interior;means for controlling fluid flow within the interior, the controlling means having a translating means with a bore and an elastomeric member sealing the bore in the closed mode,the interior of the housing having a flow path that includes at least a portion of the bore of the translating means,the flow path having an open mode volume when the valve is in the open mode, the fluid path also having a closed mode volume when the valve is in the closed mode, the open mode volume being substantially equal to the closed mode volume, and movement of the translating means causing substantially no volumetric change within any part of the flow path when the valve transitions between the open and closed modes.
  • 42. The medical valve as defined by claim 41 wherein the translating means comprises a translating member.
  • 43. The medical valve as defined by claim 41 wherein the controlling means comprises a valve mechanism.
  • 44. The medical valve as defined by claim 41 wherein the flow path has a volume that remains substantially constant as the valve transitions between the open mode and the closed mode.
  • 45. The medical valve as defined by claim 41 wherein the flow path comprises the at least a portion of the bore and a second portion, the translating means extending through the second portion of the flow path.
  • 46. The medical valve as defined by claim 41 wherein the interior also includes means for receiving the translating means, the receiving means being outside of the flow path, the translating means extending into the receiving means when the valve is in the closed mode.
  • 47. The medical valve as defined by claim 41 wherein the translating means has a substantially static shape as the valve transitions between the open mode and the closed mode.
  • 48. The medical valve as defined by claim 41 wherein the valve substantially has neither a positive push nor a drawback when the valve transitions from the open mode to the closed mode.
  • 49. The medical valve as defined by claim 41 wherein the valve substantially has neither a positive push nor a drawback when the valve transitions from the closed mode to the open mode.
  • 50. The medical valve as defined by claim 41 wherein the interior housing has a receiving chamber for receiving the translating means, the receiving chamber having a tapered seal that seals the receiving chamber.
PRIORITY

This patent application claims priority from and is a continuation-in-part of U.S. patent application Ser. No. 10/291,448, filed Nov. 7, 2002, entitled, “ANTI-DRAWBACK MEDICAL VALVE,” and naming Charles F. Ganem as inventor, the disclosure of which is incorporated herein, in its entirety, by reference. As a result of the priority claim, this patent application also claims priority from provisional U.S. Patent Application No. 60/350,738, filed Nov. 13, 2001, the disclosure of which also is incorporated herein, and its entirety, by reference. This patent application also claims priority from Provisional U.S. Patent Application No. 60/645,644, filed Jan. 21, 2005, entitled, “ANTI-DRAWBACK MEDICAL VALVE,” assigned to Nypro Inc. of Clinton, Mass., and naming Brian L. Newton and Andrew L. Cote, Sr. as inventors, the disclosure of which is incorporated herein, in its entirety, by reference.

US Referenced Citations (172)
Number Name Date Kind
2594405 Deters Apr 1952 A
2693801 Foreman Nov 1954 A
2705501 Frizsch et al. Apr 1955 A
2756740 Deane Jul 1956 A
2899975 Fernandez Aug 1959 A
2999499 Willett Sep 1961 A
3087492 Garth Apr 1963 A
3105511 Murphy, Jr. Oct 1963 A
3192949 De See Jul 1965 A
3385301 Harautuneian May 1968 A
3399677 Gould et al. Sep 1968 A
3416567 Von Dardel et al. Dec 1968 A
3506005 Gilio et al. Apr 1970 A
3538950 Porteners Nov 1970 A
3570484 Steer Mar 1971 A
3572375 Rosenberg Mar 1971 A
3726282 Patel Apr 1973 A
3806086 Cloyd Apr 1974 A
3831629 Mackal et al. Aug 1974 A
3838843 Bernhard Oct 1974 A
3923065 Nozick et al. Dec 1975 A
3965910 Fischer Jun 1976 A
3994293 Ferro Nov 1976 A
4063555 Ulinder Dec 1977 A
4080965 Phillips Mar 1978 A
4094195 Friswell et al. Jun 1978 A
4094196 Friswell Jun 1978 A
4116201 Shah Sep 1978 A
4121585 Becker, Jr. Oct 1978 A
4143853 Abramson Mar 1979 A
4223808 Williams et al. Sep 1980 A
4300571 Waldbillig Nov 1981 A
4324239 Gordon et al. Apr 1982 A
4333455 Bodicky Jun 1982 A
4334551 Pfister Jun 1982 A
4344435 Aubin Aug 1982 A
4387879 Tauschinski Jun 1983 A
4401432 Schwartz Aug 1983 A
4421296 Stephens Dec 1983 A
4458480 Irwin Jul 1984 A
4496348 Genese et al. Jan 1985 A
4498658 Mikiya Feb 1985 A
4534758 Akers et al. Aug 1985 A
4535820 Raines Aug 1985 A
4550785 Hibbard et al. Nov 1985 A
4551136 Mandl Nov 1985 A
4585435 Vaillancourt Apr 1986 A
4596557 Pexa Jun 1986 A
4611973 Birdwell Sep 1986 A
4617015 Foltz Oct 1986 A
4661110 Fortier et al. Apr 1987 A
4675003 Hooven Jun 1987 A
4681132 Lardner Jul 1987 A
4683905 Vigneau et al. Aug 1987 A
4683916 Raines Aug 1987 A
4698061 Makaryk et al. Oct 1987 A
4710168 Schwab et al. Dec 1987 A
4712583 Pelmulder et al. Dec 1987 A
4743235 Waldbillig et al. May 1988 A
4745950 Mathieu May 1988 A
4749003 Leason Jun 1988 A
4752287 Kurtz et al. Jun 1988 A
4752292 Lopez et al. Jun 1988 A
4758224 Siposs Jul 1988 A
4776369 Lardner et al. Oct 1988 A
4809679 Shimonaka et al. Mar 1989 A
4816020 Brownell Mar 1989 A
4819684 Zaugg et al. Apr 1989 A
4830331 Vindum May 1989 A
4850978 Dudar et al. Jul 1989 A
4874377 Newgard et al. Oct 1989 A
4915687 Sivert Apr 1990 A
4917668 Haindl Apr 1990 A
4935010 Cox et al. Jun 1990 A
4966199 Ruschke Oct 1990 A
5006114 Rogers et al. Apr 1991 A
5041087 Loo et al. Aug 1991 A
5048537 Messinger Sep 1991 A
5049128 Duquette Sep 1991 A
5059175 Hanover et al. Oct 1991 A
5065783 Ogle, II Nov 1991 A
5080654 Picha et al. Jan 1992 A
5085645 Purdy et al. Feb 1992 A
5100394 Dudar et al. Mar 1992 A
5108380 Herlitze et al. Apr 1992 A
5147333 Raines Sep 1992 A
5171230 Eland et al. Dec 1992 A
5184652 Fan Feb 1993 A
5199947 Lopez et al. Apr 1993 A
5201715 Masters Apr 1993 A
5203775 Frank et al. Apr 1993 A
5215538 Larkin Jun 1993 A
5221271 Nicholson et al. Jun 1993 A
5230706 Duquette Jul 1993 A
5242393 Brimhall et al. Sep 1993 A
5242432 DeFrank Sep 1993 A
5269771 Thomas et al. Dec 1993 A
5280876 Atkins Jan 1994 A
5300034 Behnke et al. Apr 1994 A
5320328 Decloux et al. Jun 1994 A
5330435 Vaillancourt Jul 1994 A
5349984 Weinheimer et al. Sep 1994 A
5360413 Leason et al. Nov 1994 A
5380306 Brinon Jan 1995 A
5390898 Smedley et al. Feb 1995 A
5401255 Sutherland et al. Mar 1995 A
5439451 Collinson et al. Aug 1995 A
5465938 Werge et al. Nov 1995 A
5474536 Bonaldo Dec 1995 A
5474544 Lynn Dec 1995 A
5509433 Paradis Apr 1996 A
5509912 Vaillancourt et al. Apr 1996 A
5520666 Choudhury et al. May 1996 A
5533708 Atkinson et al. Jul 1996 A
5533983 Haining Jul 1996 A
5549566 Elias et al. Aug 1996 A
5569209 Roitman Oct 1996 A
5569235 Ross et al. Oct 1996 A
5573516 Tyner Nov 1996 A
5578059 Patzer Nov 1996 A
5616129 Mayer Apr 1997 A
5616130 Mayer Apr 1997 A
5620434 Brony Apr 1997 A
5674206 Allton et al. Oct 1997 A
5676346 Leinsing Oct 1997 A
5685866 Lopez Nov 1997 A
5694686 Lopez Dec 1997 A
5695466 Lopez et al. Dec 1997 A
5699821 Paradis Dec 1997 A
5700248 Lopez Dec 1997 A
5730418 Feith et al. Mar 1998 A
5749861 Guala et al. May 1998 A
RE35841 Frank et al. Jul 1998 E
5806831 Paradis Sep 1998 A
5820601 Mayer Oct 1998 A
5921264 Paradis Jul 1999 A
6029946 Doyle Feb 2000 A
6036171 Weinheimer et al. Mar 2000 A
6039302 Cote, Sr. et al. Mar 2000 A
6048335 Mayer Apr 2000 A
6050978 Orr et al. Apr 2000 A
6063062 Paradis May 2000 A
6068011 Paradis May 2000 A
6079432 Paradis Jun 2000 A
6089541 Weinheimer et al. Jul 2000 A
6152900 Mayer Nov 2000 A
6228069 Barth et al. May 2001 B1
6245048 Fangrow, Jr. et al. Jun 2001 B1
6290206 Doyle Sep 2001 B1
6325099 Bunschoten et al. Dec 2001 B1
6344033 Jepson et al. Feb 2002 B1
6428520 Lopez et al. Aug 2002 B1
6482188 Rogers et al. Nov 2002 B1
6543745 Enerson Apr 2003 B1
6581906 Pott et al. Jun 2003 B2
6595964 Finley et al. Jul 2003 B2
6595981 Huet Jul 2003 B2
6609696 Enerson Aug 2003 B2
6669673 Lopez Dec 2003 B2
6745998 Doyle Jun 2004 B2
6755391 Newton et al. Jun 2004 B2
6883778 Newton et al. Apr 2005 B1
7037302 Vaillancourt May 2006 B2
20030050610 Newton et al. Mar 2003 A1
20030093061 Ganem May 2003 A1
20030098430 Leinsing et al. May 2003 A1
20030141477 Miller Jul 2003 A1
20040073171 Rogers et al. Apr 2004 A1
20040206924 Newton et al. Oct 2004 A1
20070218757 Guala Sep 2007 A1
20080190485 Guala Aug 2008 A1
20080275405 Newton et al. Nov 2008 A1
Foreign Referenced Citations (16)
Number Date Country
0268480 May 1988 EP
0629418 Dec 1994 EP
1243285 Sep 2002 EP
2079162 Jan 1982 GB
WO 8302559 Aug 1983 WO
WO 9311828 Jun 1993 WO
WO 9600107 Jan 1996 WO
WO 9739791 Oct 1997 WO
WO 9822178 May 1998 WO
WO 9826835 Jun 1998 WO
WO 9839594 Sep 1998 WO
WO 0044433 Aug 2000 WO
WO 0120218 Mar 2001 WO
WO 03018104 Mar 2003 WO
WO 03018105 Mar 2003 WO
WO 2004060466 Jul 2004 WO
Related Publications (1)
Number Date Country
20050165365 A1 Jul 2005 US
Provisional Applications (2)
Number Date Country
60350738 Nov 2001 US
60645644 Jan 2005 US
Continuation in Parts (1)
Number Date Country
Parent 10291448 Nov 2002 US
Child 11058381 US